Last reviewed · How we verify
Xromi
At a glance
| Generic name | Xromi |
|---|---|
| Also known as | hydroxycarbamide oral solution 100mg/ml, liquid hydroxyurea, LO1XX05 |
| Sponsor | Nova Laboratories Limited |
| Target | Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Chronic myeloid leukemia
- Hb SS disease
- Hemoglobin SS disease with crisis
- Malignant melanoma
- Malignant tumor of head and/or neck
- Malignant tumor of ovary
- Sickling disorder due to hemoglobin S
Common side effects
- Neutropenia
- Rash Popular
- Thrombocytopenia
- Diarrhea
- GGT Increased
- Absolute Reticulocyte Count Decreased
- Alopecia
- Nail Discolouration
- Rash
- Nausea
- Vomiting
- Stomatitis
Serious adverse events
- Myelosuppression
- Malignancies
- Pulmonary Fibrosis
- Hemolytic Anemia
- Hepatitis
- Systemic Lupus Erythematosus
- Convulsions
- Interstitial Lung Disease
- Pneumonitis
- Drug-Induced Fever Requiring Hospitalization
Key clinical trials
- PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
- Pharmacokinetics of Oral Hydroxyurea Solution (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xromi CI brief — competitive landscape report
- Xromi updates RSS · CI watch RSS
- Nova Laboratories Limited portfolio CI